Journal of Drugs in Dermatology - Ramipril in rheumatoid arthritis
This study is currently recruiting patients. Verified and sponsored by Sanofi-Aventis. The present study is designed to evaluate the hypothesis that the Angiotensin Converting Enzyme (ACE) inhibitor Ramipril improves vascular function and reduces markers of low-grade chronic inflammation and oxidative stress in patients with rheumatoid arthritis. Condition Intervention Phase Arthritis Drug: Ramipril Phase II Rheumatoid Phase III Study ID Numbers: HOE498/6007
Related Results
RAMIPRIL.Sandoz launches ramiprilCutaneous vasculitis secondary to ramiprilRamipril cuts diabetes riskRamipril-associated hepatotoxicity
ClinicalTrials.gov Identifier: NCT00273533
COPYRIGHT 2006 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2008 Gale, Cengage Learning
